CODX Co-Diagnostics Inc

Price (delayed)

$3.86

Market cap

$130.39M

P/E Ratio

4.15

Dividend/share

N/A

EPS

$0.93

Enterprise value

$44.84M

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using ...

Highlights
The stock's price to earnings (P/E) is 32% less than its last 4 quarters average of 6.1
The company's debt fell by 12% QoQ
Co-Diagnostics's quick ratio has surged by 76% QoQ but it has decreased by 10% YoY
The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter
CODX's EPS is down by 43% year-on-year and by 31% since the previous quarter
CODX's net income is down by 39% year-on-year and by 31% since the previous quarter

Key stats

What are the main financial stats of CODX
Market
Shares outstanding
33.78M
Market cap
$130.39M
Enterprise value
$44.84M
Valuations
Price to earnings (P/E)
4.15
Price to book (P/B)
0.91
Price to sales (P/S)
1.6
EV/EBIT
1.34
EV/EBITDA
1.3
EV/Sales
0.57
Earnings
Revenue
$78.22M
EBIT
$33.49M
EBITDA
$34.38M
Free cash flow
$24.66M
Per share
EPS
$0.93
Free cash flow per share
$0.76
Book value per share
$4.25
Revenue per share
$2.41
TBVPS
$3.65
Balance sheet
Total assets
$160.84M
Total liabilities
$16.37M
Debt
$489,166
Equity
$144.47M
Working capital
$107.85M
Liquidity
Debt to equity
0
Current ratio
17.06
Quick ratio
16.12
Net debt/EBITDA
-2.49
Margins
EBITDA margin
43.9%
Gross margin
87.2%
Net margin
35.8%
Operating margin
37.9%
Efficiency
Return on assets
18.8%
Return on equity
21.3%
Return on invested capital
165.2%
Return on capital employed
21.7%
Return on sales
42.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CODX stock price

How has the Co-Diagnostics stock price performed over time
Intraday
-6.08%
1 week
-41.69%
1 month
-33.22%
1 year
-65.04%
YTD
-56.77%
QTD
-31.19%

Financial performance

How have Co-Diagnostics's revenue and profit performed over time
Revenue
$78.22M
Gross profit
$68.23M
Operating income
$29.62M
Net income
$28M
Gross margin
87.2%
Net margin
35.8%
CODX's operating income is down by 41% YoY and by 35% from the previous quarter
CODX's net income is down by 39% year-on-year and by 31% since the previous quarter
Co-Diagnostics's operating margin has decreased by 27% YoY and by 16% from the previous quarter
The company's net margin fell by 25% YoY and by 11% QoQ

Growth

What is Co-Diagnostics's growth rate over time

Valuation

What is Co-Diagnostics stock price valuation
P/E
4.15
P/B
0.91
P/S
1.6
EV/EBIT
1.34
EV/EBITDA
1.3
EV/Sales
0.57
CODX's EPS is down by 43% year-on-year and by 31% since the previous quarter
The stock's price to earnings (P/E) is 32% less than its last 4 quarters average of 6.1
The P/B is 96% below the 5-year quarterly average of 20.9 and 52% below the last 4 quarters average of 1.9
The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter
The P/S is 100% below the 5-year quarterly average of 1214.9 and 33% below the last 4 quarters average of 2.4
The revenue has contracted by 22% from the previous quarter and by 19% YoY

Efficiency

How efficient is Co-Diagnostics business performance
The ROA has plunged by 70% YoY and by 39% from the previous quarter
CODX's return on equity has dropped by 67% year-on-year and by 38% since the previous quarter
CODX's return on invested capital is down by 39% since the previous quarter and by 24% year-on-year
CODX's return on sales is down by 18% year-on-year and by 12% since the previous quarter

Dividends

What is CODX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CODX.

Financial health

How did Co-Diagnostics financials performed over time
Co-Diagnostics's total liabilities has soared by 196% YoY but it has decreased by 30% from the previous quarter
The current ratio has soared by 77% from the previous quarter but it has decreased by 11% YoY
The company's debt is 100% lower than its equity
The equity has surged by 66% year-on-year but it has declined by 2.2% since the previous quarter
The company's debt fell by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.